SCHEMBL6747583

SCHEMBL6747583

Cc1nc(-c2ccc(F)cc2)c(-c2ccnc3ccccc23)o1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 4/20 0.54
ALOX5 P09917 2/20 0.48
PTGS2 P35354 6/20 0.47
PTGS1 P23219 3/20 0.47
GRM4 Q14833 1/20 0.44
MAPK13 O15264 2/20 0.44
MAPK12 P53778 2/20 0.44
MAPK11 Q15759 2/20 0.44
MAPT P10636 2/20 0.42
RAB9A P51151 2/20 0.42
RECQL P46063 1/20 0.42
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
CASP1 P29466 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4033235 0.78 TGFBR1 (0.60) MAPK14CYP1A2TGFBR1
SCHEMBL5318173 0.76 GRM4 (0.62) MAPK14ALOX5GRM4MAPK13MAPK12
SCHEMBL18805529 0.76 GRM4 (0.62) MAPK14ALOX5GRM4MAPK13MAPK12
SCHEMBL31014179 0.76 GRM4 (0.62) MAPK14ALOX5GRM4MAPK13MAPK12
SCHEMBL31194856 0.74 PTGS2 (0.74) MAPK14PTGS2PTGS1MAPK13MAPK12
SCHEMBL15637816 0.73 MAPK14 (0.54) MAPK14ALOX5GRM4MAPK13MAPK12
SCHEMBL4032807 0.72 TGFBR1 (0.57) MAPK14RAB9AKDM4ENPC1ALDH1A1
SCHEMBL14519488 0.71 MAPK14 (0.55) MAPK14ALOX5GRM4MAPK13MAPK12
SCHEMBL1387350 0.71 MAPK14 (0.71) MAPK14PTGS2PTGS1MAPK13MAPK12
SCHEMBL1387279 0.71 MAPK14 (0.71) MAPK14PTGS2PTGS1MAPK13MAPK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040106793-A1 Oxazoles for treating cytokine mediated diseases SMITHKLINE BEECHAM CORPORATION 2004-06-03 US disclosed
EP-1306377-A2 Pyridyl-oxazoles and their use as cytokines inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2003-05-02 EP disclosed
US-20020169173-A1 Oxazoles for treating cytokine mediated diseases SMITHKLINE BEECHAM CORPORATION 2002-11-14 US disclosed
US-6288062-B1 INTERLEUKIN AND TUMOR NECROSIS FACTOR INHIBITORS; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS SMITHKLINE BEECHAM CORPORATION 2001-09-11 US disclosed
EP-0727998-A4 OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORP (US) 1997-03-19 EP disclosed
EP-0727998-A1 OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1996-08-28 EP disclosed
WO-1995013067-A1 OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES SMITHKLINE BEECHAM CORPORATION (US) 1995-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040106793-A1 Oxazoles for treating cytokine mediated diseases IL2, IL17A, IL5 MAPK14 709/4885ALOX5 176/4885PTGS2 339/4885
US-20020169173-A1 Oxazoles for treating cytokine mediated diseases IL17A, IL4I1, IL2 MAPK14 870/4885ALOX5 59/4885PTGS2 804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.